skip to Main Content

VIDEO: Niraparib-Ipilimumab Maintenance Prevents Advanced Pancreatic Cancer Progression

Newsfeed image, light gray text on dark gray background
In this video, Kim A. Reiss, MD, discussed the results of a randomized phase 1b/2 study of niraparib plus nivolumab or ipilimumab in patients with advanced pancreatic cancer, which were presented in a poster session at ASCO2022.

Maintenance with niraparib (Zejula, GlaxoSmithKine) plus ipilimumab (Yervoy, Bristol Myers Squibb) was effective in preventing progression in patients with advanced pancreatic cancer and led to a PFS of approximately 8 months, Reiss, assistant professor of medicine at the Hospital of the University of Pennsylvania, said. In comparison, niraparib plus nivolumab (Opdivo, Bristol Myers Squibb) was not effective in preventing progression, with an approximate PFS of 1.8 months, she said. Read more . . . 

Back To Top